Premium
Clinical anti‐inflammatory efficacy of arofylline, a new selective phosphodiesterase‐4 inhibitor, in dogs with atopic dermatitis
Author(s) -
Ferrer L.,
Alberola J.,
Queralt M.,
Brazis P.,
Rabanal R.,
Llenas J.,
Puigdemont A.
Publication year - 1999
Publication title -
veterinary record
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.261
H-Index - 99
eISSN - 2042-7670
pISSN - 0042-4900
DOI - 10.1136/vr.145.7.191
Subject(s) - medicine , prednisone , atopic dermatitis , adverse effect , anesthesia , gastroenterology , surgery , dermatology
Forty atopic dogs were studied for 28 days after the oral administration of four randomised treatments: (A) arofylline (1 mg/kg) twice daily for four weeks; (B) prednisone (0.5 mg/kg) twice daily for the first week, once a day during the second week and every 48 hours for the remaining two weeks; (C) prednisone following the same protocol but at a dose of 0‐25 mg/kg; or (D) arofylline (1 mg/kg) twice daily for four weeks plus prednisone (0.25 mg/kg) following the same protocol as in (B) and (C). The degree of pruritus and skin lesions and the side effects were evaluated and graded from 0 to 3 before and weekly during the treatments. In all cases there was a progressive clinical improvement in the clinical signs, with no statistical differences among the four treatments. However, many of the dogs treated with arofylline vomited and had adverse gastrointestinal signs.